MYCT1

Across TCGA pan-cancer cohorts, MYCT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYCT1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYCT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYCT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where MYCT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.443	<.001	48	view →
LUAD	DFS	Tertile	III,IV	0.383	0.967	.001	25	view →
GBM	OS	Quartile	All	0.302	0.755	.003	4	view →
LSCC	DFS	Tertile	All	0.897	0.971	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYCT1–CCRCC (DFS)

Open the CCRCC breakdown →